Welcome to our comprehensive learning program on screening, diagnosing, and managing IgA nephropathy (IgAN). This program aims to provide you with a deep understanding of screening techniques, referral procedures, treatment selection, drug distribution and safety and monitoring requirements in IgAN management. Furthermore, this activity encourages care coordination between interdisciplinary team members to improve the co-management of patients with IgAN.
CME/CE Accreditation Information
This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility. Through this interactive, small-group activity, participants will review brief modules and patient cases to identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL and also integrate protocols to manage CRS and ICANS effectively when managing patients. The group will gather for a live discussion via Zoom to share and exchange ideas on this topic.
CME/CE Accreditation Information
This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.
CME/CE Accreditation Information
